Special Issue "Antisense Therapy"
A special issue of Biomedicines (ISSN 2227-9059).
Deadline for manuscript submissions: closed (30 November 2017)
This Special Issue, “Antisense Therapy”, will focus on the progress of antisense oligonucleotides as therapy for various conditions. Issues that need addressing are Duchenne muscular dystrophy (DMD) and exon skipping; spinal muscular dystrophy and antisense oligonucleotides; new chemistries; enhancing delivery; genetic modifiers; miRNAs and antagomirs.
We cordially invite authors in the field to submit review articles or original research to this Special Issue of Biomedicines.
Dr. Linda Popplewell
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- SMA (Spinal muscular atrophy)
- clinical trials